mutation germline ou somatique BRCA1/2, mutation PIK3CA, mutation ESR1, amplification HER2,...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`RF-BREAST-HIGH-RISK-BIOLOGY`
Type	Signal d’alerte
État	pending_clinical_signoff
Maladies	`DIS-BREAST`
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Origine du drapeau rouge

Définition	La mutation germline ou somatique BRCA1/2, la mutation PIK3CA, la mutation ESR1, l'amplification HER2 ou la positivité PD-L1 ouvrent chacune des indications distinctes basées sur le biomarqueur.
Direction clinique	intensifier
Catégorie	high-risk-biology

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "BIO-BRCA-GERMLINE",
      "value": "positive"
    },
    {
      "finding": "BIO-PIK3CA-MUTATION",
      "value": "positive"
    },
    {
      "finding": "BIO-HER2-SOLID",
      "value": "positive"
    },
    {
      "finding": "BIO-PDL1-EXPRESSION",
      "value": "positive"
    },
    {
      "finding": "esr1_mutation",
      "value": true
    }
  ],
  "type": "biomarker"
}

Notes

Biomarker-driven branching is the dominant breast-cancer pattern. Each positive biomarker opens distinct targeted-therapy options: BRCA → olaparib/talazoparib; PIK3CA → alpelisib; HER2-amp → HER2- targeted agents; PD-L1 → pembrolizumab + chemo; ESR1 → elacestrant. The Algorithm decision_tree resolves these per disease state.

Utilisé par

Algorithmes

ALGO-BREAST-1L - ALGO-BREAST-1L